Preferred Label : Anti-SARS-CoV-2 Monoclonal Antibodies AZD5156;
NCIt synonyms : Cilgavimab/AZD3152; AZD1061 Plus AZD3152; AZD1061/AZD3152; Cilgavimab Plus AZD3152;
NCIt definition : A combination of two neutralizing human monoclonal antibodies, cilgavimab, a neutralizing
human monoclonal antibody directed against severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) spike (S) protein, and AZD3152, a long-acting neutralizing human monoclonal
antibody directed against SARS-CoV-2, derived from B-cells of convalescent patients
with SARS-CoV-2 infection, that can potentially be used for passive immunization against
Coronavirus disease 2019 (COVID-19). Upon administration of anti-SARS-CoV-2 monoclonal
antibodies AZD5156, cilgavimab specifically targets and binds to the SARS-CoV-2 S
protein, thereby blocking viral attachment and entry into human cells and may thereby
neutralize SARS-CoV-2. Anti-SARS-CoV-2 monoclonal antibody AZD3152 also neutralizes
SARS-CoV-2. This may slow the progression of the disease and accelerate recovery,
and may potentially provide temporary protection against infection with SARS-CoV-2.
S protein, usually found on the surface of SARS-CoV-2, plays an essential role in
the infection pathway of the SARS-CoV-2 virus.;
Molecule name : AZD-5156; AZD 5156;
NCI Metathesaurus CUI : CL1907350;
Origin ID : C200076;
UMLS CUI : C5854471;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
